This white paper presents a comprehensive analysis of one of the world's largest real-world clinical datasets in stem cell therapy, comprising over 15,000 cases accumulated over more than a decade.

The dataset provides a regulatory-grade real-world evidence (RWE) platform that bridges clinical practice and the development and commercialization of Advanced Therapy Medicinal Products (ATMPs). By integrating multi-centre clinical operations with rigorous manufacturing controls, the study demonstrates the scalability, safety, and reproducibility required for global therapeutic deployment.

Key contributions of this work include:

• Large-scale clinical validation : Continuous accumulation of over 15,000 cases across multiple disease areas, enabling robust insights into safety and clinical implementation.
• Manufacturing and quality standardization : Demonstration of reproducibility through defined Critical Quality Attributes (CQA), Critical Process Parameters (CPP), potency assays, and release criteria, ensuring consistent therapeutic performance.
• Mechanistic framework : Identification of core therapeutic mechanisms of mesenchymal stem cells (MSCs), including paracrine signaling, immunomodulation, and tissue regeneration.
• Regulatory alignment : Evidence supporting ATMP licensing, including successful regulatory positioning in the United Kingdom and the United Arab Emirates.
• Scalable clinical model : A multi-centre, multi-indication framework enabling expansion across global healthcare systems and regulatory environments.
• Commercialization strategy : A platform-based approach leveraging out-licensing, co-development partnerships, and geographic expansion across APAC, EU, and GCC regions.

Unlike conventional clinical studies, which are often limited in scale and duration, this dataset represents a qualitative shift in regenerative evidence generation, enabling real-world validation of both clinical and manufacturing consistency.

This establishes a foundational model for the transition from real-world clinical practice to globally deployable regenerative therapeutics, positioning Helene Biomed as a scalable ATMP platform company in the evolving biopharmaceutical landscape.